Truculent
发表于 2025-3-25 06:58:41
http://reply.papertrans.cn/87/8614/861399/861399_21.png
hurricane
发表于 2025-3-25 07:58:55
http://reply.papertrans.cn/87/8614/861399/861399_22.png
aspersion
发表于 2025-3-25 15:33:35
http://reply.papertrans.cn/87/8614/861399/861399_23.png
创造性
发表于 2025-3-25 16:45:26
Wilfried Schütteythropoietin action are under development and will enter clinical trials soon. These aspects make it essential to screen patients for the presence of anti-EPO antibodies. Despite the lack of a common calibrator, screening assays for the detection of anti-erythropoietin antibodies are available.
Factual
发表于 2025-3-25 21:05:56
Caja Thimm,Susanne Augensteinquired for optimal and individualized therapies, and Ab detection induced during therapy. In an effort to assess the clinical relevance of in vitro Ab measurements, many investigators distinguish between ‘binding’ Abs (BAbs) and in vitro ‘neutralizing’ Abs (NAbs) even though such a distinction may n
BUCK
发表于 2025-3-26 00:43:23
http://reply.papertrans.cn/87/8614/861399/861399_26.png
MERIT
发表于 2025-3-26 06:20:31
Alexander Brockd therapies with recombinant human IFN-beta. As autoAbs, they neutralize wild-type IFN-beta, they cross-react with both currently used IFNbeta biopharmaceuticals, but not IFN-alpha, and they interfere with biological and immunometric assays for IFN-beta in vitro and in vivo. Although anti- IFN-beta
Negligible
发表于 2025-3-26 10:01:36
http://reply.papertrans.cn/87/8614/861399/861399_28.png
paradigm
发表于 2025-3-26 13:26:56
http://reply.papertrans.cn/87/8614/861399/861399_29.png
Accede
发表于 2025-3-26 20:39:44
http://reply.papertrans.cn/87/8614/861399/861399_30.png